Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for infusion for intravenous use. It provides passive immunity and is employed to treat primary and secondary immunodeficiency diseases, as well as certain immune‑mediated disorders in patients of all ages.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Ig Vena is used in immunoglobulin replacement therapy to restore antibody levels in various immune‑deficient and immune‑mediated conditions.

- Primary immunodeficiency diseases: replaces deficient IgG to reduce frequency and severity of infections. - Secondary immunodeficiency (e.g., chemotherapy‑induced): supplies exogenous antibodies to support immune function during immunosuppressive treatment. - Kawasaki disease: administered to reduce inflammation and prevent coronary artery complications. - Immune thrombocytopenic purpura (ITP): modulates immune response to increase platelet counts. - Idiopathic thrombocytopenic purpura: provides immunomodulation to improve platelet survival.

Ig Vena may be associated with a range of infusion‑related and immunologic adverse reactions.

Common Side Effects: - Headache - Fever or chills - Nausea - Fatigue

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Thromboembolic events (e.g., stroke, myocardial infarction) - Acute renal failure - Aseptic meningitis

Prior to initiating Ig Vena therapy, several safety considerations should be evaluated. - Screen for IgA deficiency: assess risk of anti‑IgA antibodies that may cause severe reactions. - Monitor renal function: evaluate baseline creatinine and adjust infusion rate in patients with renal impairment. - Assess thrombotic risk: consider history of clotting disorders before high‑dose infusions. - Observe for infusion reactions: start at a slow rate and watch for signs of hypersensitivity. - Avoid use in patients with known severe IgA antibodies: contraindicated due to risk of anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause infection or reduced vaccine effectiveness. - High‑dose aspirin or anticoagulants: increase risk of bleeding when combined with IVIG‑related platelet dysfunction.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents (e.g., rituximab, cyclophosphamide): may alter IgG levels and require dose adjustments. - Diuretics: heightened risk of renal stress; monitor kidney function. - Cytokine‑targeted therapies: potential for additive immune modulation; observe clinical response.